Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.114236 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Somnath Mukherjee und 22 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: somnath.mukherjee@ouh.nhs.uk. Hauptthemen laut MEDLINE: Nelfinavir, Pancreatic Neoplasms, Chemoradiotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Cancer Research UK.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: somnath.mukherjee@ouh.nhs.uk.
- Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
- Oncology Clinical Trials Office (OCTO), Department of Oncology, University of Oxford, Oxford, UK.
- Department of Oncology, University of Cambridge, Cambridge, UK; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
- UCL Cancer Institute, University College London Hospitals NHS Foundation Trust, London, UK.
- The Christie Hospital, The Christie Hospitals NHS Foundation Trust, Manchester, UK.
Förderung
- Cancer Research UK
Zitieren
APA
Mukherjee, S., Qi, C., Shaw, R., Jones, C. M., Bridgewater, J. A., Radhakrishna, G., Patel, N., Holmes, J., Virdee, P. S., Tranter, B., Parsons, P., Falk, S., Wasan, H. S., Ajithkumar, T. V., Holyoake, D., Roy, R., Scott-Brown, M., Hurt, C. N., O'Neill, E., …, & Corrie, P. (2024). Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114236
Vancouver
Mukherjee S, Qi C, Shaw R, Jones CM, Bridgewater JA, Radhakrishna G, et al. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114236
BibTeX
@article{Mukherjee2024,
author = {Mukherjee, Somnath and Qi, Cathy and Shaw, Rachel and Jones, Christopher M and Bridgewater, John A and Radhakrishna, Ganesh and Patel, Neel and Holmes, Jane and Virdee, Pradeep S and Tranter, Bethan and Parsons, Philip and Falk, Stephen and Wasan, Harpreet S and Ajithkumar, Thankamma V and Holyoake, Daniel and Roy, Rajarshi and Scott-Brown, Martin and Hurt, Christopher N and O'Neill, Eric and Sebag-Montefiore, David and Maughan, Tim S and Hawkins, Maria A and Corrie, Pippa},
title = {Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.114236}
}
EUVIMED